Oridonin Alters the Expression Profiles of MicroRNAs in BxPC-3 Human Pancreatic Cancer Cells

Overview

Journal BMC Complement Altern Med

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2015 Apr 17

PMID 25880988

Citations 8

Authors

Zhifang Gui

Shuquan Li

Xing Liu

Bin Xu

Jian Xu

Affiliations

Soon will be listed here.

Abstract

Background: Oridonin, an ingredient used in traditional Chinese medicine, has been demonstrated to play an important role in antitumour effects, but the mechanism underlying its antitumour properties is still not clear.

Methods: To verify the anti-cancer effects of oridonin via a miRNA-dependent mechanism, comprehensive miRNA expression profiling of oridonin-treated BxPC-3 human pancreatic cancer cells was performed using a miRNA microarray assay based on Sanger miR-Base Release 20, followed by a validation using real-time PCR. MicroRNA target prediction and Gene Ontology and KEGG pathway analysis were performed to investigate possible pathways involved.

Results: The results showed that 105 miRNAs were significantly differentially expressed (signal reading >500, p ≤ 0.01, |Log2-value| ≥1) in oridonin-treated BxPC-3 human pancreatic cancer cells.

Conclusions: Our data indicates that oridonin inhibits BxPC-3 cells probably through regulating the expression of miRNAs. Interruption of miRNA profiling may provide new therapeutic methods for the clinical treatment of pancreatic cancer.

Citing Articles

Oridonin from : An emerging potential in cancer therapy - A comprehensive review.

Ali M, Khan N, Ali A, Akram H, Zafar N, Imran K Food Sci Nutr. 2024; 12(5):3046-3067.

PMID: 38726411 PMC: 11077219. DOI: 10.1002/fsn3.3986.

Advances in the treatment of pancreatic cancer with traditional Chinese medicine.

Zhang Y, Xu H, Li Y, Sun Y, Peng X Front Pharmacol. 2023; 14:1089245.

PMID: 37608897 PMC: 10440824. DOI: 10.3389/fphar.2023.1089245.

Herbals and Plants in the Treatment of Pancreatic Cancer: A Systematic Review of Experimental and Clinical Studies.

Triantafillidis J, Triantafyllidi E, Sideris M, Pittaras T, Papalois A Nutrients. 2022; 14(3).

PMID: 35276978 PMC: 8839014. DOI: 10.3390/nu14030619.

Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity.

Li X, Zhang C, Ma W, Xie X, Huang Q Front Pharmacol. 2021; 12:645824.

PMID: 34295243 PMC: 8289702. DOI: 10.3389/fphar.2021.645824.

Inferring the Disease-Associated miRNAs Based on Network Representation Learning and Convolutional Neural Networks.

Xuan P, Sun H, Wang X, Zhang T, Pan S Int J Mol Sci. 2019; 20(15).

PMID: 31349729 PMC: 6696449. DOI: 10.3390/ijms20153648.

References

Ikezoe T, Chen S, Tong X, Heber D, Taguchi H, Koeffler H . Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol. 2003; 23(4):1187-93. View

Tsuchiya S, Okuno Y, Tsujimoto G . MicroRNA: biogenetic and functional mechanisms and involvements in cell differentiation and cancer. J Pharmacol Sci. 2006; 101(4):267-70. DOI: 10.1254/jphs.cpj06013x. View

Zhu Q, Hong A, Sheng N, Zhang X, Matejko A, Jun K . microParaflo biochip for nucleic acid and protein analysis. Methods Mol Biol. 2008; 382:287-312. DOI: 10.1007/978-1-59745-304-2_19. View

Hanoun N, Delpu Y, Suriawinata A, Bournet B, Bureau C, Selves J . The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin Chem. 2010; 56(7):1107-18. DOI: 10.1373/clinchem.2010.144709. View

Xu X, Chen H, Lin Y, Hu Z, Mao Y, Wu J . MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met. Mol Cells. 2013; 36(1):62-8. PMC: 3887926. DOI: 10.1007/s10059-013-0044-7. View

Park J, Henry J, Jiang J, Esau C, Gusev Y, Lerner M . miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun. 2011; 406(4):518-23. PMC: 3069485. DOI: 10.1016/j.bbrc.2011.02.065. View

Bae S, Lee E, Cha H, Kim K, Yoon Y, Lee H . Resveratrol alters microRNA expression profiles in A549 human non-small cell lung cancer cells. Mol Cells. 2011; 32(3):243-9. PMC: 3887628. DOI: 10.1007/s10059-011-1037-z. View

Josson S, Gururajan M, Hu P, Shao C, Chu G, Zhau H . miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer. Clin Cancer Res. 2014; 20(17):4636-46. PMC: 4155061. DOI: 10.1158/1078-0432.CCR-14-0305. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

10.

Hao J, Zhang S, Zhou Y, Hu X, Shao C . MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in pancreatic cancer. FEBS Lett. 2010; 585(1):207-13. DOI: 10.1016/j.febslet.2010.11.039. View

11.

Xu B, Shen W, Liu X, Zhang T, Ren J, Fan Y . Oridonin inhibits BxPC-3 cell growth through cell apoptosis. Acta Biochim Biophys Sin (Shanghai). 2015; 47(3):164-73. DOI: 10.1093/abbs/gmu134. View

12.

Nalls D, Tang S, Rodova M, Srivastava R, Shankar S . Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One. 2011; 6(8):e24099. PMC: 3166078. DOI: 10.1371/journal.pone.0024099. View

13.

Ohuchida K, Mizumoto K, Lin C, Yamaguchi H, Ohtsuka T, Sato N . MicroRNA-10a is overexpressed in human pancreatic cancer and involved in its invasiveness partially via suppression of the HOXA1 gene. Ann Surg Oncol. 2012; 19(7):2394-402. DOI: 10.1245/s10434-012-2252-3. View

14.

Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F . MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A. 2005; 102(50):18081-6. PMC: 1312381. DOI: 10.1073/pnas.0506216102. View

15.

Chen R, Xu B, Chen S, Chen S, Zhang T, Ren J . Effect of oridonin-mediated hallmark changes on inflammatory pathways in human pancreatic cancer (BxPC-3) cells. World J Gastroenterol. 2014; 20(40):14895-903. PMC: 4209552. DOI: 10.3748/wjg.v20.i40.14895. View

16.

Wang S, Zhong Z, Wan J, Tan W, Wu G, Chen M . Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells. Am J Chin Med. 2013; 41(1):177-96. DOI: 10.1142/S0192415X13500134. View

17.

Li C, Nie H, Wang M, Su L, Li J, Yu B . MicroRNA-409-3p regulates cell proliferation and apoptosis by targeting PHF10 in gastric cancer. Cancer Lett. 2012; 320(2):189-97. DOI: 10.1016/j.canlet.2012.02.030. View

18.

Cho W . OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007; 6:60. PMC: 2098778. DOI: 10.1186/1476-4598-6-60. View

19.

Bu H, Luo J, Chen H, Zhang J, Li H, Guo H . Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway. Int J Oncol. 2012; 41(3):949-58. DOI: 10.3892/ijo.2012.1519. View

20.

Wu K, Hu G, He X, Zhou P, Li J, He B . MicroRNA-424-5p suppresses the expression of SOCS6 in pancreatic cancer. Pathol Oncol Res. 2013; 19(4):739-48. DOI: 10.1007/s12253-013-9637-x. View